The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases
- 1 July 1985
- journal article
- clinical trial
- Published by Springer Nature in Inflammation Research
- Vol. 16 (5), 313-317
- https://doi.org/10.1007/bf01982865
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- PROGNOSTIC VALUE OF BETA-THROMBOGLOBULIN IN PATIENTS WITH TRANSIENT CEREBRAL ISCHAEMIAThe Lancet, 1983
- Plasma beta-thromboglobulin as a measure of platelet activityThe American Journal of Cardiology, 1982
- Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonistInflammation Research, 1982
- Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.BMJ, 1982
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981
- Platelet Activation during Exercise-Induced Myocardial IschemiaNew England Journal of Medicine, 1980
- ELEVATED β-THROMBOGLOBULIN LEVELS AND CIRCULATING PLATELET AGGREGATES IN DIABETIC MICROANGIOPATHYThe Lancet, 1978
- Platelet abnormalities in ischemic heart diseaseThe American Journal of Cardiology, 1973
- Platelet Function Studies in Coronary Artery DiseaseCirculation, 1973
- A Biphasic Response of Platelets to SerotoninScandinavian Journal of Haematology, 1970